Novel Therapeutic Approach for Human T-cell Malignancies
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This multicenter translational study, with prospective and retrospective samples, aims to identify new strategies to selectively eliminate neoplastic T cells by modulating intracellular ROS levels. Interactions between drugs capable of activating the apoptotic process (e.g., Venetoclax) and drugs capable of altering ROS homeostasis (e.g., inhibitors of the enzyme glucose-6-phosphate dehydrogenase) will be examined. The most promising compounds will be selected based on results obtained in vitro on cell lines and PDX already available in the laboratory, and then will be assayed ex vivo in cells obtained from patients with resistant/refractory T-cell neoplasms.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjenci z nowotworem komórek T (białaczką lub chłoniakiem) przed lub po jego rozwoju
- •Pacjenci w wieku powyżej 18 lat
- •Mężczyźni i kobiety
- •Chętni do podpisania zgody na udział w badaniu
✗ Disqualifies
- •Poważna choroba lub stan zdrowia uniemożliwiający standardowe leczenie
- •Niekontrolowana aktywna infekcja
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 6, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
Istituto Nazionale Tumori Fondazione G.Pascale
Naples, Italy
Istituto Oncologico Veneto
Padova, Italy
Trial contact
Michele Gottardi, MD
GianLuca De Salvo, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/7/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.